Indeed, in patients with GVHD, strategies that aim to reduce intestinal permeability and downregulate MLCK1 expression, as well as inflammatory factors, can greatly alleviate GVHD-related IBD and improve patient outcomes. Here, MYLK is linked to inflammatory bowel disease.